Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GHB1589M is a preclinical inhaled oligonucleotide therapeutic being developed by Gatehouse Bio for the treatment of idiopathic pulmonary fibrosis (IPF). Discovered using the company's AI-driven Code-Breaker™ platform, which identifies disease-driving small RNA (sRNA) isoforms, the drug is designed to target specific molecular mechanisms underlying lung fibrosis. By utilizing an inhaled delivery method, GHB1589M aims to provide direct therapeutic action within the lung tissue while minimizing systemic exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GHB1589M.